Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice

被引：0

作者：

Fedyanin, M. ^{[1
]}

Elsnukaeva, H. ^{[1
]}

Demidova, I. ^{[2
]}

Stroyakovskiy, D. ^{[3
]}

Shelygin, Y. ^{[4
]}

Tsukanov, A. ^{[5
]}

Panina, M. ^{[6
]}

Moiseenko, F. ^{[7
]}

Karpenko, E. ^{[8
]}

Bolotina, L. ^{[8
]}

Kudryavtseva, A. ^{[9
]}

Filipenko, M. ^{[10
]}

Oskorbin, I. ^{[10
]}

Vladimirova, L. Y. ^{[11
]}

Timoshkina, N. N. ^{[12
]}

Kit, O. I. ^{[13
]}

Stroganova, A. ^{[14
]}

Dranko, S. ^{[14
]}

Tryakin, A. ^{[1
]}

Tjulandin, S. ^{[1
]}

机构：

[1] Minist Hlth Russian Federat NN Blokhin NMRCO, NN Blokhin Natl Med Res Ctr Oncol, Fed State Budgetary Inst, Clin Pharmacol & Chemotherapy, Moscow, Russia

[2] Moscow City Oncol Hosp 62, Moscow Dept Hlth, Genet, Moscow, Russia

[3] Moscow City Oncol Hosp 62, Moscow Dept Hlth, Chemotherapy, Moscow, Russia

[4] Minister Hlth, State Sci Ctr Coloproctol, Moscow, Russia

[5] Minister Hlth, State Sci Ctr Coloproctol, Genet, Moscow, Russia

[6] Minister Hlth, State Sci Ctr Coloproctol, Oncol Dept, Moscow, Russia

[7] St Petersburg Clin Res & Pract Ctr Specialized Ty, Oncol, St Petersburg, Russia

[8] Minist Hlth Russian Federat RF, Branch Natl Med Res Radiol Ctr, RA Hertsen Moscow Oncol Res Inst, Chemotherapy, Moscow, Russia

[9] Russian Acad Sci, EIMB Engelhardt Inst Mol Biol, Lab Postgen Studies, Moscow, Russia

[10] Inst Clin Biol & Fundamental Med, Genet, Novosibirsk, Russia

[11] Natl Med Res Ctr Oncol, Med Oncol Dept, Rostov Na Donu, Russia

[12] Natl Med Res Ctr Oncol, Lab Mol Oncol, Rostov Na Donu, Russia

[13] Natl Med Res Ctr Oncol, Rostov Na Donu, Russia

[14] Minist Hlth Russian Federat NN Blokhin NMRCO, NN Blokhin Natl Med Res Ctr Oncol, Fed State Budgetary Inst, Genet, Moscow, Russia

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.969

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

448P

引用

页码：S557 / S558

页数：2

共 50 条

[1] Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group
Fernandez, Mercedes Salgado
Lopez, Margarita Reboredo
Rua, Marta Covela
Candamio, Sonia
Gonzalez-Villarroel, Paula
Sanchez-Cousido, Luis Felipe
Grana, Begona
Carral-Maseda, Alberto
Cameselle-Garcia, Soledad
Varela Pose, Vanesa
Gallardo-Martin, Maria Elena
Martinez-Lago, Nieves
TARGETED ONCOLOGY, 2024, 19 (04) : 565 - 573
[2] Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma
Mae Nakano
Yoshifumi Shimada
Yoshifumi Matsumoto
Takuro Saiki
Qiliang Zhou
Kenta Sasaki
Masato Moriyama
Kosuke Yoshihara
Manabu Natsumeda
Yoko Kuriyama
Yasumasa Takii
Gen Watanabe
Hajime Umezu
Shujiro Okuda
Takeshi Ikeuchi
Toshifumi Wakai
Yasuo Saijo
Clinical Journal of Gastroenterology, 2022, 15 : 413 - 418
[3] Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma
Nakano, Mae
Shimada, Yoshifumi
Matsumoto, Yoshifumi
Saiki, Takuro
Zhou, Qiliang
Sasaki, Kenta
Moriyama, Masato
Yoshihara, Kosuke
Natsumeda, Manabu
Kuriyama, Yoko
Takii, Yasumasa
Watanabe, Gen
Umezu, Hajime
Okuda, Shujiro
Ikeuchi, Takeshi
Wakai, Toshifumi
Saijo, Yasuo
CLINICAL JOURNAL OF GASTROENTEROLOGY, 2022, 15 (02) : 413 - 418
[4] A method to assess KRAS/BRAF genotype in patients with metastatic colorectal cancer (mCRC) elligible for anti-EGFR therapies
Lamy, A.
Labourier, E.
Prigneau, O.
Di Fiore, F.
Sesbouea, R.
Sabourin, J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[5] Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients
Hafliger, E.
Boccaccino, A.
El-Khoury, R.
Perret, A.
Pietrantonio, F.
Pilla, L.
Lecomte, T.
Scartozzi, M.
Soularue, E.
Salvatore, L.
Bourgeois, V.
Salati, M.
Vaillant, J. N.
Gallois, C.
Lonardi, S.
Cremolini, C.
Taieb, J.
ANNALS OF ONCOLOGY, 2021, 32 : S554 - S554
[6] Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
Rachiglio, Anna Maria
Forgione, Laura
Pasquale, Raffaella
Barone, Carlo Antonio
Maiello, Evaristo
Antonuzzo, Lorenzo
Cassata, Antonino
Tonini, Giuseppe
Bordonaro, Roberto
Rosati, Gerardo
Zaniboni, Alberto
Lonardi, Sara
Ferrari, Daris
Frassineti, Giovanni Luca
Tamberi, Stefano
Pisconti, Salvatore
Di Fabio, Francesca
Roma, Cristin
Orlandi, Armando
Latiano, Tiziana
Damato, Angela
Tortora, Giampaolo
Pinto, Carmine
Normanno, Nicola
CANCERS, 2022, 14 (04)
[7] Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
Schulz, Martin S.
Wolf, Sebastian
Struck, Vera
Thomas, Niklas
Husman, Gabriele
Zeuzem, Stefan
Koch, Christine
Trojan, Joerg
Schnitzbauer, Andreas Anton
Bechstein, Wolf Otto
Waidmann, Oliver
CANCERS, 2022, 14 (07)
[8] Use of anti-EGFR agents among elderly patients with metastatic colorectal cancer (mCRC).
D'Silva, Ashley James
Dotan, Efrat
Kloth, Dwight D.
Beck, Andrew
Cohen, Steven J.
Denlinger, Crystal Shereen
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[9] Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
Cremolini, Chiara
Berenato, Rosa
Morano, Federica
Moretto, Roberto
Perrone, Federica
Tamborini, Elena
Rossini, Daniele
Gloghini, Annunziata
Busico, Adele
Fuca, Giovanni
Baratelli, Chiara
Tamburini, Emiliano
Capone, Iolanda
Volpi, Chiara Costanza
Milione, Massimo
Di Maio, Massimo
Fontanini, Gabriella
De Braud, Filippo
Falcone, Alfredo
Pietrantonio, Filippo
CANCER RESEARCH, 2017, 77
[10] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
S. Abdelwahab
A. Azmy
H. Abdel-aziz
H. Salim
A. Mahmoud
Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1487 - 1492

← 1 2 3 4 5 →